Current Management and Future Perspective in Pleural Mesothelioma
Abstract
:Simple Summary
Abstract
1. Introduction
2. Histological and Molecular Characteristics
2.1. Histomorphology, Histological Assessment and Molecular Classification
2.2. Molecular Aberrations
2.3. Tumor Microenvironment and Heterogeneity
3. Surgical Diagnostic and Treatment
3.1. Videothoracoscopy as Gold Standard
3.2. Surgical Treatment in Multimodal Setting
3.3. Surgical Methods in Palliation
4. Systemic Treatment
4.1. Firstline Treatment
4.1.1. Systemic Chemotherapy
4.1.2. Tumor Treating Fields
4.1.3. Immune Checkpoint Inhibition
4.2. Salvage Treatment
4.2.1. Chemotherapy Regimens
4.2.2. Immune Checkpoint Inhibition
4.3. Systemic Treatment in Resectable Stage
Immune Checkpoint Inhibitors
4.4. Further Trials of Interest and Future Perspectives
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Robinson, B.W.; Lake, R.A. Advances in malignant mesothelioma. N. Engl. J. Med. 2005, 353, 1591–1603. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, T.; Sun, X.M.; Wu, L. High Time for Complete Ban on Asbestos Use in Developing Countries. JAMA Oncol. 2019, 5, 779–780. [Google Scholar] [CrossRef] [PubMed]
- Janes, S.M.; Alrifai, D.; Fennell, D.A. Perspectives on the Treatment of Malignant Pleural Mesothelioma. N. Engl. J. Med. 2021, 385, 1207–1218. [Google Scholar] [CrossRef] [PubMed]
- Flanagan, D. Minerals Yearbook (2020 Tables-Only Release); U.S. Geological Survey: Fairfax County, VA, USA; U.S. Department of the Interior: Washington, DC, USA, 2020. Available online: https://www.usgs.gov/centers/national-minerals-information-center/asbestos-statistics-and-information (accessed on 7 January 2022).
- Kindler, H.L.; Millard, F.; Herndon, J.E., 2nd; Vogelzang, N.J.; Suzuki, Y.; Green, M.R. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001, 31, 311–317. [Google Scholar] [CrossRef]
- Vogelzang, N.J. Multimodality therapy in mesothelioma: Role of chemotherapy. Thorac. Surg Clin. 2004, 14, 531–542. [Google Scholar] [CrossRef] [PubMed]
- Vogelzang, N.J.; Rusthoven, J.J.; Symanowski, J.; Denham, C.; Kaukel, E.; Ruffie, P.; Gatzemeier, U.; Boyer, M.; Emri, S.; Manegold, C.; et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003, 21, 2636–2644. [Google Scholar] [CrossRef]
- Steele, J.P.; Shamash, J.; Evans, M.T.; Gower, N.H.; Tischkowitz, M.D.; Rudd, R.M. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2000, 18, 3912–3917. [Google Scholar] [CrossRef]
- Vorobiof, D.A.; Rapoport, B.L.; Chasen, M.R.; Abratt, R.P.; Cronje, N.; Fourie, L.; McMichael, G.; Hacking, D. Malignant pleural mesothelioma: A phase II trial with docetaxel. Ann. Oncol. 2002, 13, 412–415. [Google Scholar] [CrossRef]
- Flores, R.M. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: The Memorial Sloan-Kettering experience. Lung Cancer 2005, 49 (Suppl. S1), S71–S74. [Google Scholar] [CrossRef]
- Zalcman, G.; Mazieres, J.; Margery, J.; Greillier, L.; Audigier-Valette, C.; Moro-Sibilot, D.; Molinier, O.; Corre, R.; Monnet, I.; Gounant, V.; et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial. Lancet 2016, 387, 1405–1414. [Google Scholar] [CrossRef]
- Quispel-Janssen, J.; van der Noort, V.; de Vries, J.F.; Zimmerman, M.; Lalezari, F.; Thunnissen, E.; Monkhorst, K.; Schouten, R.; Schunselaar, L.; Disselhorst, M.; et al. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. J. Thorac. Oncol. 2018, 13, 1569–1576. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zalcman, G.; Mazieres, J.; Greillier, L.; Brosseau, S.; Lantuejoul, S.; Do, P.; Bylicki, O.; Monnet, I.; Corre, R.; Audigier-Valette, C.; et al. Second/third-line nivolumab vs. nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD). Ann. Oncol. 2019, 30, v747. [Google Scholar] [CrossRef]
- Disselhorst, M.J.; Quispel-Janssen, J.; Lalezari, F.; Monkhorst, K.; de Vries, J.F.; van der Noort, V.; Harms, E.; Burgers, S.; Baas, P. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial. Lancet Respir. Med. 2019, 7, 260–270. [Google Scholar] [CrossRef]
- Alley, E.W.; Lopez, J.; Santoro, A.; Morosky, A.; Saraf, S.; Piperdi, B.; van Brummelen, E. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017, 18, 623–630. [Google Scholar] [CrossRef]
- Desai, A.; Karrison, T.; Rose, B.; Tan, Y.; Hill, B.; Pemberton, E.; Straus, C.; Seiwert, T.; Kindler, H.L. OA08.03 Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis. J. Thorac. Oncol. 2018, 13, S339. [Google Scholar] [CrossRef] [Green Version]
- Hassan, R.; Thomas, A.; Nemunaitis, J.J.; Patel, M.R.; Bennouna, J.; Chen, F.L.; Delord, J.P.; Dowlati, A.; Kochuparambil, S.T.; Taylor, M.H.; et al. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019, 5, 351–357. [Google Scholar] [CrossRef]
- Maio, M.; Scherpereel, A.; Calabro, L.; Aerts, J.; Perez, S.C.; Bearz, A.; Nackaerts, K.; Fennell, D.A.; Kowalski, D.; Tsao, A.S.; et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017, 18, 1261–1273. [Google Scholar] [CrossRef]
- Nakajima, E.C.; Vellanki, P.J.; Larkins, E.; Chatterjee, S.; Mishra-Kalyani, P.S.; Bi, Y.; Qosa, H.; Liu, J.; Zhao, H.; Biable, M.; et al. FDA Approval Summary: Nivolumab in Combination with Ipilimumab for the Treatment of Unresectable Malignant Pleural Mesothelioma. Clin. Cancer Res. 2022, 28, 446–451. [Google Scholar] [CrossRef]
- Baas, P.; Scherpereel, A.; Nowak, A.K.; Fujimoto, N.; Peters, S.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Jahan, T.; Antonia, S.; et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet 2021, 397, 375–386. [Google Scholar] [CrossRef]
- Brosseau, S.; Danel, C.; Scherpereel, A.; Mazieres, J.; Lantuejoul, S.; Margery, J.; Greillier, L.; Audigier-Valette, C.; Gounant, V.; Antoine, M.; et al. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort. Clin. Lung Cancer 2019, 20, e564–e575. [Google Scholar] [CrossRef]
- de Boer, N.L.; van Kooten, J.P.; Burger, J.W.A.; Verhoef, C.; Aerts, J.; Madsen, E.V.E. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: Rationale and design of the MESOPEC trial. BMJ Open 2019, 9, e026779. [Google Scholar] [CrossRef]
- Belderbos, R.A.; Baas, P.; Berardi, R.; Cornelissen, R.; Fennell, D.A.; van Meerbeeck, J.P.; Scherpereel, A.; Vroman, H.; Aerts, J. A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial. Transl. Lung Cancer Res. 2019, 8, 280–285. [Google Scholar] [CrossRef]
- Danson, S.J.; Conner, J.; Edwards, J.G.; Blyth, K.G.; Fisher, P.M.; Muthana, M.; Salawu, A.; Taylor, F.; Hodgkinson, E.; Joyce, P.; et al. Oncolytic herpesvirus therapy for mesothelioma—A phase I/IIa trial of intrapleural administration of HSV1716. Lung Cancer 2020, 150, 145–151. [Google Scholar] [CrossRef]
- Kuryk, L.; Haavisto, E.; Garofalo, M.; Capasso, C.; Hirvinen, M.; Pesonen, S.; Ranki, T.; Vassilev, L.; Cerullo, V. Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model. Int. J. Cancer 2016, 139, 1883–1893. [Google Scholar] [CrossRef] [Green Version]
- Mayor, M.; Zeltsman, M.; McGee, E.; Adusumilli, P.S. A regional approach for CAR T-cell therapy for mesothelioma: From mouse models to clinical trial. Immunotherapy 2016, 8, 491–494. [Google Scholar] [CrossRef] [Green Version]
- Zeltsman, M.; Dozier, J.; McGee, E.; Ngai, D.; Adusumilli, P.S. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. Transl. Res. 2017, 187, 1–10. [Google Scholar] [CrossRef]
- Waller, D.A.; Dawson, A.G. Randomized controlled trials in malignant pleural mesothelioma surgery-mistakes made and lessons learned. Ann. Transl. Med. 2017, 5, 240. [Google Scholar] [CrossRef] [Green Version]
- Woodard, G.A.; Jablons, D.M. Surgery for pleural mesothelioma, when it is indicated and why: Arguments against surgery for malignant pleural mesothelioma. Transl. Lung Cancer Res. 2020, 9, S86–S91. [Google Scholar] [CrossRef]
- Cho, B.C.J.; Donahoe, L.; Bradbury, P.A.; Leighl, N.; Keshavjee, S.; Hope, A.; Pal, P.; Cabanero, M.; Czarnecka, K.; McRae, K.; et al. Surgery for malignant pleural mesothelioma after radiotherapy (SMART): Final results from a single-centre, phase 2 trial. Lancet Oncol. 2021, 22, 190–197. [Google Scholar] [CrossRef]
- Popat, S.; Baas, P.; Faivre-Finn, C.; Girard, N.; Nicholson, A.G.; Nowak, A.K.; Opitz, I.; Scherpereel, A.; Reck, M. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann. Oncol. 2021, 33, 129–142. [Google Scholar] [CrossRef]
- World Health, O. Thoracic Tumors, 5th ed.; Lyon Cedex International Agency for Research on Cancer: Lyon, France, 2021; Volume 5. [Google Scholar]
- Bueno, R.; Stawiski, E.W.; Goldstein, L.D.; Durinck, S.; De Rienzo, A.; Modrusan, Z.; Gnad, F.; Nguyen, T.T.; Jaiswal, B.S.; Chirieac, L.R.; et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 2016, 48, 407–416. [Google Scholar] [CrossRef]
- Marques, M.; Tranchant, R.; Risa-Ebri, B.; Suarez-Solis, M.L.; Fernandez, L.C.; Carrillo-de-Santa-Pau, E.; Del Pozo, N.; Martinez de Villarreal, J.; Meiller, C.; Allory, Y.; et al. Combined MEK and PI3K/p110beta Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features. Cancer Res. 2020, 80, 843–856. [Google Scholar] [CrossRef] [Green Version]
- Nicholson, A.G.; Sauter, J.L.; Nowak, A.K.; Kindler, H.L.; Gill, R.R.; Remy-Jardin, M.; Armato III, S.G.; Fernandez-Cuesta, L.; Bueno, R.; Alcala, N.J.J.o.T.O. EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: Towards a more multidisciplinary approach. J. Thorac. Oncol. 2020, 15, 29–49. [Google Scholar] [CrossRef]
- Dacic, S.; Le Stang, N.; Husain, A.; Weynand, B.; Beasley, M.B.; Butnor, K.; Chapel, D.; Gibbs, A.; Klebe, S.; Lantuejoul, S.; et al. Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas. Mod. Pathol. 2020, 33, 255–262. [Google Scholar] [CrossRef]
- Alcala, N.; Mangiante, L.; Le-Stang, N.; Gustafson, C.E.; Boyault, S.; Damiola, F.; Alcala, K.; Brevet, M.; Thivolet-Bejui, F.; Blanc-Fournier, C.J.E. Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. EBioMedicine 2019, 48, 191–202. [Google Scholar] [CrossRef] [Green Version]
- Kojima, M.; Kajino, K.; Momose, S.; Wali, N.; Hlaing, M.T.; Han, B.; Yue, L.; Abe, M.; Fujii, T.; Ikeda, K.; et al. Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression. Respir. Res. 2020, 21, 187. [Google Scholar] [CrossRef]
- Travis, W.D.; Brambilla, E.; Van Schil, P.; Scagliotti, G.V.; Huber, R.M.; Sculier, J.-P.; Vansteenkiste, J.; Nicholson, A.G. Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification. Eur. Respir. J. 2011, 38, 239–243. [Google Scholar] [CrossRef] [Green Version]
- Warth, A.; Muley, T.; Meister, M.; Stenzinger, A.; Thomas, M.; Schirmacher, P.; Schnabel, P.A.; Budczies, J.; Hoffmann, H.; Weichert, W. The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival. J. Clin. Oncol. 2012, 30, 1438–1446. [Google Scholar] [CrossRef]
- Alchami, F.S.; Attanoos, R.L.; Bamber, A.R. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: An analysis of 191 patients with pleural malignant mesothelioma. J. Clin. Pathol. 2017, 70, 179–182. [Google Scholar] [CrossRef]
- Bilecz, A.; Stockhammer, P.; Theegarten, D.; Kern, I.; Jakopovic, M.; Samarzija, M.; Klikovits, T.; Hoda, M.A.; Döme, B.; Oberndorfer, F.; et al. Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid pleural mesothelioma. Histopathology 2020, 77, 55–66. [Google Scholar] [CrossRef]
- Brčić, L.; Jakopović, M.; Brčić, I.; Klarić, V.; Milošević, M.; Sepac, A.; Samaržija, M.; Seiwerth, S. Reproducibility of histological subtyping of malignant pleural mesothelioma. Virchows Arch.: Int. J. Pathol. 2014, 465, 679–685. [Google Scholar] [CrossRef] [Green Version]
- Miettinen, M.; McCue, P.A.; Sarlomo-Rikala, M.; Rys, J.; Czapiewski, P.; Wazny, K.; Langfort, R.; Waloszczyk, P.; Biernat, W.; Lasota, J.; et al. GATA3: A multispecific but potentially useful marker in surgical pathology: A systematic analysis of 2500 epithelial and nonepithelial tumors. Am. J. Surg. Pathol. 2014, 38, 13–22. [Google Scholar] [CrossRef]
- Tanaka, H.; Akiyama, Y.; Kitamura, A.; Matsumoto, N.; Tomita, M.; Kataoka, H. Malignant mesothelioma with squamous differentiation. Histopathology 2018, 72, 1216–1220. [Google Scholar] [CrossRef]
- Galateau-Salle, F.; Vignaud, J.M.; Burke, L.; Gibbs, A.; Brambilla, E.; Attanoos, R.; Goldberg, M.; Launoy, G.; Mesopath, G. Well-differentiated papillary mesothelioma of the pleura: A series of 24 cases. Am. J. Surg. Pathol. 2004, 28, 534–540. [Google Scholar] [CrossRef]
- de Reynies, A.; Jaurand, M.C.; Renier, A.; Couchy, G.; Hysi, I.; Elarouci, N.; Galateau-Salle, F.; Copin, M.C.; Hofman, P.; Cazes, A.; et al. Molecular classification of malignant pleural mesothelioma: Identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin. Cancer Res. 2014, 20, 1323–1334. [Google Scholar] [CrossRef] [Green Version]
- Hmeljak, J.; Sanchez-Vega, F.; Hoadley, K.A.; Shih, J.; Stewart, C.; Heiman, D.; Tarpey, P.; Danilova, L.; Drill, E.; Gibb, E.A.; et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018, 8, 1548–1565. [Google Scholar] [CrossRef] [Green Version]
- Guo, G.; Chmielecki, J.; Goparaju, C.; Heguy, A.; Dolgalev, I.; Carbone, M.; Seepo, S.; Meyerson, M.; Pass, H.I. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Cancer Res. 2015, 75, 264–269. [Google Scholar] [CrossRef] [Green Version]
- Attanoos, R.L.; Churg, A.; Galateau-Salle, F.; Gibbs, A.R.; Roggli, V.L. Malignant Mesothelioma and Its Non-Asbestos Causes. Arch. Pathol. Lab. Med. 2018, 142, 753–760. [Google Scholar] [CrossRef] [Green Version]
- Wang, A.; Papneja, A.; Hyrcza, M.; Al-Habeeb, A.; Ghazarian, D. Gene of the month: BAP1. J. Clin. Pathol. 2016, 69, 750–753. [Google Scholar] [CrossRef]
- De Rienzo, A.; Chirieac, L.R.; Hung, Y.P.; Severson, D.T.; Freyaldenhoven, S.; Gustafson, C.E.; Dao, N.T.; Meyerovitz, C.V.; Oster, M.E.; Jensen, R.V.; et al. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma. J. Pathol. 2021, 253, 68–79. [Google Scholar] [CrossRef]
- Hwang, H.C.; Pyott, S.; Rodriguez, S.; Cindric, A.; Carr, A.; Michelsen, C.; Thompson, K.; Tse, C.H.; Gown, A.M.; Churg, A. BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas. Am. J. Surg. Pathol. 2016, 40, 714–718. [Google Scholar] [CrossRef] [PubMed]
- McGregor, S.M.; Dunning, R.; Hyjek, E.; Vigneswaran, W.; Husain, A.N.; Krausz, T. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma. Hum. Pathol. 2015, 46, 1670–1678. [Google Scholar] [CrossRef] [PubMed]
- Ascoli, V.; Cozzi, I.; Vatrano, S.; Izzo, S.; Giorcelli, J.; Romeo, E.; Carnovale-Scalzo, C.; Grillo, L.R.; Facciolo, F.; Visca, P.; et al. Mesothelioma families without inheritance of a BAP1 predisposing mutation. Cancer Genet. 2016, 209, 381–387. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Righi, L.; Duregon, E.; Vatrano, S.; Izzo, S.; Giorcelli, J.; Rondón-Lagos, M.; Ascoli, V.; Ruffini, E.; Ventura, L.; Volante, M.; et al. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study. J. Thorac. Oncol. 2016, 11, 2006–2017. [Google Scholar] [CrossRef] [Green Version]
- Guo, Z.; Carbone, M.; Zhang, X.; Su, D.; Sun, W.; Lou, J.; Gao, Z.; Shao, D.; Chen, J.; Zhang, G.; et al. Improving the Accuracy of Mesothelioma Diagnosis in China. J. Thorac. Oncol. 2017, 12, 714–723. [Google Scholar] [CrossRef] [Green Version]
- Foulkes, W.D.; Flanders, T.Y.; Pollock, P.M.; Hayward, N.K. The CDKN2A (p16) Gene and Human Cancer. Mol. Med. 1997, 3, 5–20. [Google Scholar] [CrossRef] [Green Version]
- Cairns, P.; Mao, L.; Merlo, A.; Lee, D.J.; Schwab, D.; Eby, Y.; Tokino, K.; van der Riet, P.; Blaugrund, J.E.; Sidransky, D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 1994, 265, 415–417. [Google Scholar] [CrossRef] [Green Version]
- Dacic, S.; Kothmaier, H.; Land, S.; Shuai, Y.; Halbwedl, I.; Morbini, P.; Murer, B.; Comin, C.; Galateau-Salle, F.; Demirag, F.; et al. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Arch. 2008, 453, 627–635. [Google Scholar] [CrossRef]
- Kobayashi, N.; Toyooka, S.; Yanai, H.; Soh, J.; Fujimoto, N.; Yamamoto, H.; Ichihara, S.; Kimura, K.; Ichimura, K.; Sano, Y.; et al. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer 2008, 62, 120–125. [Google Scholar] [CrossRef] [Green Version]
- López-Ríos, F.; Chuai, S.; Flores, R.; Shimizu, S.; Ohno, T.; Wakahara, K.; Illei, P.B.; Hussain, S.; Krug, L.; Zakowski, M.F.; et al. Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction. Cancer Res. 2006, 66, 2970–2979. [Google Scholar] [CrossRef] [Green Version]
- Illei, P.B.; Rusch, V.W.; Zakowski, M.F.; Ladanyi, M. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin. Cancer Res. 2003, 9, 2108–2113. [Google Scholar] [PubMed]
- Markowitz, P.; Patel, M.; Groisberg, R.; Aisner, J.; Jabbour, S.K.; De, S.; Ganesan, S.; Malhotra, J. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. Cancer Treat. Res. Commun. 2020, 25, 100232. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Luo, J.-L.; Sun, Q.; Harber, J.; Dawson, A.G.; Nakas, A.; Busacca, S.; Sharkey, A.J.; Waller, D.; Sheaff, M.T.; et al. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat. Commun. 2021, 12, 1751. [Google Scholar] [CrossRef] [PubMed]
- Betti, M.; Aspesi, A.; Ferrante, D.; Sculco, M.; Righi, L.; Mirabelli, D.; Napoli, F.; Rondon-Lagos, M.; Casalone, E.; Vignolo Lutati, F.; et al. Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes. Genes Chromosomes Cancer 2018, 57, 573–583. [Google Scholar] [CrossRef]
- Betti, M.; Aspesi, A.; Biasi, A.; Casalone, E.; Ferrante, D.; Ogliara, P.; Gironi, L.C.; Giorgione, R.; Farinelli, P.; Grosso, F.; et al. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma. Cancer Lett. 2016, 378, 120–130. [Google Scholar] [CrossRef]
- Pilarski, R.; Carlo, M.; Cebulla, C.; Abdel-Rahman, M. BAP1 tumor predisposition syndrome. In GeneReviews(®); Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Mirzaa, G., Amemiya, A., Eds.; University of Washington: Seattle, WA, USA, 1993. [Google Scholar]
- Carbone, M.; Harbour, J.W.; Brugarolas, J.; Bononi, A.; Pagano, I.; Dey, A.; Krausz, T.; Pass, H.I.; Yang, H.; Gaudino, G. Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. Cancer Discov. 2020, 10, 1103–1120. [Google Scholar] [CrossRef]
- Quetel, L.; Meiller, C.; Assié, J.B.; Blum, Y.; Imbeaud, S.; Montagne, F.; Tranchant, R.; de Wolf, J.; Caruso, S.; Copin, M.C.; et al. Genetic alterations of malignant pleural mesothelioma: Association with tumor heterogeneity and overall survival. Molecular Oncol. 2020, 14, 1207–1223. [Google Scholar] [CrossRef]
- Giovannini, M.; Robanus-Maandag, E.; van der Valk, M.; Niwa-Kawakita, M.; Abramowski, V.; Goutebroze, L.; Woodruff, J.M.; Berns, A.; Thomas, G. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000, 14, 1617–1630. [Google Scholar] [CrossRef]
- Jongsma, J.; van Montfort, E.; Vooijs, M.; Zevenhoven, J.; Krimpenfort, P.; van der Valk, M.; van de Vijver, M.; Berns, A. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008, 13, 261–271. [Google Scholar] [CrossRef] [Green Version]
- Tranchant, R.; Quetel, L.; Tallet, A.; Meiller, C.; Renier, A.; de Koning, L.; de Reynies, A.; Le Pimpec-Barthes, F.; Zucman-Rossi, J.; Jaurand, M.C.; et al. Co-occurring Mutations of Tumor Suppressor Genes, LATS2 and NF2, in Malignant Pleural Mesothelioma. Clin. Cancer Res. 2017, 23, 3191–3202. [Google Scholar] [CrossRef] [Green Version]
- Burt, B.M.; Rodig, S.J.; Tilleman, T.R.; Elbardissi, A.W.; Bueno, R.; Sugarbaker, D.J. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 2011, 117, 5234–5244. [Google Scholar] [CrossRef] [PubMed]
- Chu, G.J.; van Zandwijk, N.; Rasko, J.E.J. The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. Front. Oncol. 2019, 9, 1366. [Google Scholar] [CrossRef] [PubMed]
- Suzuki, K.; Kadota, K.; Sima, C.S.; Sadelain, M.; Rusch, V.W.; Travis, W.D.; Adusumilli, P.S. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol. Immunother. 2011, 60, 1721–1728. [Google Scholar] [CrossRef] [PubMed]
- Blum, Y.; Meiller, C.; Quetel, L.; Elarouci, N.; Ayadi, M.; Tashtanbaeva, D.; Armenoult, L.; Montagne, F.; Tranchant, R.; Renier, A.; et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat. Commun. 2019, 10, 1333. [Google Scholar] [CrossRef]
- Alay, A.; Cordero, D.; Hijazo-Pechero, S.; Aliagas, E.; Lopez-Doriga, A.; Marín, R.; Palmero, R.; Llatjós, R.; Escobar, I.; Ramos, R.; et al. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. J. Immunother. Cancer 2021, 9, e001601. [Google Scholar] [CrossRef]
- Lee, H.S.; Jang, H.J.; Choi, J.M.; Zhang, J.; de Rosen, V.L.; Wheeler, T.M.; Lee, J.S.; Tu, T.; Jindra, P.T.; Kerman, R.H.; et al. Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. JCI Insight 2018, 3, e98575. [Google Scholar] [CrossRef] [Green Version]
- Patil, N.S.; Righi, L.; Koeppen, H.; Zou, W.; Izzo, S.; Grosso, F.; Libener, R.; Loiacono, M.; Monica, V.; Buttigliero, C.; et al. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. J. Thorac. Oncol. 2018, 13, 124–133. [Google Scholar] [CrossRef] [Green Version]
- Chirieac, L.R.; Hung, Y.P.; Foo, W.C.; Hofer, M.D.; VanderLaan, P.A.; Richards, W.G.; Sugarbaker, D.J.; Bueno, R. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer 2019, 125, 4164–4171. [Google Scholar] [CrossRef]
- Meiller, C.; Montagne, F.; Hirsch, T.Z.; Caruso, S.; de Wolf, J.; Bayard, Q.; Assié, J.-B.; Meunier, L.; Blum, Y.; Quetel, L.; et al. Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Med. 2021, 13, 113. [Google Scholar] [CrossRef]
- Oehl, K.; Vrugt, B.; Opitz, I.; Meerang, M. Heterogeneity in Malignant Pleural Mesothelioma. Int. J. Mol. Sci. 2018, 19, 1603. [Google Scholar] [CrossRef] [Green Version]
- Carbone, M.; Adusumilli, P.S.; Alexander, H.R., Jr.; Baas, P.; Bardelli, F.; Bononi, A.; Bueno, R.; Felley-Bosco, E.; Galateau-Salle, F.; Jablons, D.; et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J. Clin. 2019, 69, 402–429. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scherpereel, A.; Opitz, I.; Berghmans, T.; Psallidas, I.; Glatzer, M.; Rigau, D.; Astoul, P.; Bolukbas, S.; Boyd, J.; Coolen, J.; et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur. Respir. J. 2020, 55. [Google Scholar] [CrossRef] [PubMed]
- Van Schil, P.E.; Opitz, I.; Weder, W.; De Laet, C.; Domen, A.; Lauwers, P.; Hendriks, J.M.; Van Meerbeeck, J.P. Multimodal management of malignant pleural mesothelioma: Where are we today? Eur. Respir. J. 2014, 44, 754–764. [Google Scholar] [CrossRef] [Green Version]
- Opitz, I.; Weder, W. Pleural mesothelioma: Is the surgeon still there? Ann. Oncol. 2018, 29, 1710–1717. [Google Scholar] [CrossRef] [PubMed]
- Zahid, I.; Sharif, S.; Routledge, T.; Scarci, M. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma? Interact Cardiovasc. Thorac Surg. 2011, 12, 812–817. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Klotz, L.V.; Lindner, M.; Eichhorn, M.E.; Grutzner, U.; Koch, I.; Winter, H.; Kauke, T.; Duell, T.; Hatz, R.A. Pleurectomy/decortication and hyperthermic intrathoracic chemoperfusion using cisplatin and doxorubicin for malignant pleural mesothelioma. J. Thorac. Dis. 2019, 11, 1963–1972. [Google Scholar] [CrossRef] [PubMed]
- Flores, R.M.; Pass, H.I.; Seshan, V.E.; Dycoco, J.; Zakowski, M.; Carbone, M.; Bains, M.S.; Rusch, V.W. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. J. Thorac. Cardiovasc. Surg. 2008, 135, 620–626.e3. [Google Scholar] [CrossRef] [Green Version]
- Richards, W.G.; Zellos, L.; Bueno, R.; Jaklitsch, M.T.; Janne, P.A.; Chirieac, L.R.; Yeap, B.Y.; Dekkers, R.J.; Hartigan, P.M.; Capalbo, L.; et al. Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J. Clin. Oncol. 2006, 24, 1561–1567. [Google Scholar] [CrossRef]
- Treasure, T.; Lang-Lazdunski, L.; Waller, D.; Bliss, J.M.; Tan, C.; Entwisle, J.; Snee, M.; O’Brien, M.; Thomas, G.; Senan, S.; et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011, 12, 763–772. [Google Scholar] [CrossRef]
- Taioli, E.; Wolf, A.S.; Flores, R.M. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann. Thorac. Surg. 2015, 99, 472–480. [Google Scholar] [CrossRef]
- Bertoglio, P.; Waller, D.A. The role of thoracic surgery in the management of mesothelioma: An expert opinion on the limited evidence. Expert Rev. Respir. Med. 2016, 10, 663–672. [Google Scholar] [CrossRef] [PubMed]
- Rice, D. Standardizing surgical treatment in malignant pleural mesothelioma. Ann. Cardiothorac. Surg. 2012, 1, 497–501. [Google Scholar] [CrossRef] [PubMed]
- Kindler, H.L.; Ismaila, N.; Armato, S.G., 3rd; Bueno, R.; Hesdorffer, M.; Jahan, T.; Jones, C.M.; Miettinen, M.; Pass, H.; Rimner, A.; et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J. Clin. Oncol. 2018, 36, 1343–1373. [Google Scholar] [CrossRef] [PubMed]
- Lim, E.; Darlison, L.; Edwards, J.; Elliott, D.; Fennell, D.A.; Popat, S.; Rintoul, R.C.; Waller, D.; Ali, C.; Bille, A.; et al. Mesothelioma and Radical Surgery 2 (MARS 2): Protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open 2020, 10, e038892. [Google Scholar] [CrossRef]
- Cao, C.; Tian, D.; Park, J.; Allan, J.; Pataky, K.A.; Yan, T.D. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer 2014, 83, 240–245. [Google Scholar] [CrossRef]
- Schwartz, R.M.; Lieberman-Cribbin, W.; Wolf, A.; Flores, R.M.; Taioli, E. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma. BMC Cancer 2018, 18, 1188. [Google Scholar] [CrossRef]
- Soysal, O.; Karaoglanoglu, N.; Demiracan, S.; Topcu, S.; Tastepe, I.; Kaya, S.; Unlu, M.; Cetin, G. Pleurectomy/decortication for palliation in malignant pleural mesothelioma: Results of surgery. Eur. J. Cardiothorac. Surg. 1997, 11, 210–213. [Google Scholar] [CrossRef]
- Sugarbaker, D.J.; Gill, R.R.; Yeap, B.Y.; Wolf, A.S.; DaSilva, M.C.; Baldini, E.H.; Bueno, R.; Richards, W.G. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J. Thorac. Cardiovasc. Surg. 2013, 145, 955–963. [Google Scholar] [CrossRef] [Green Version]
- Klotz, L.V.; Gruenewald, C.; Bulut, E.L.; Eichhorn, F.; Thomas, M.; Shah, R.; Kriegsmann, M.; Schmidt, W.; Kofler, O.; Winter, H.; et al. Cytoreductive Thoracic Surgery Combined with Hyperthermic Chemoperfusion for Pleural Malignancies: A Single-Center Experience. Respiration 2021, 100, 1165–1173. [Google Scholar] [CrossRef]
- Sugarbaker, D.J. Macroscopic complete resection: The goal of primary surgery in multimodality therapy for pleural mesothelioma. J. Thorac. Oncol. 2006, 1, 175–176. [Google Scholar] [CrossRef]
- Rintoul, R.C.; Ritchie, A.J.; Edwards, J.G.; Waller, D.A.; Coonar, A.S.; Bennett, M.; Lovato, E.; Hughes, V.; Fox-Rushby, J.A.; Sharples, L.D.; et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): An open-label, randomised, controlled trial. Lancet 2014, 384, 1118–1127. [Google Scholar] [CrossRef] [Green Version]
- Matthews, C.; Freeman, C.; Sharples, L.D.; Fox-Rushby, J.; Tod, A.; Maskell, N.A.; Edwards, J.G.; Coonar, A.S.; Sivasothy, P.; Hughes, V.; et al. MesoTRAP: A feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial. BMJ Open Respir. Res. 2019, 6, e000368. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Freeman, R.K.; Ascioti, A.J.; Dake, M.; Mahidhara, R.S. A propensity-matched comparison of pleurodesis or tunneled pleural catheter for heart failure patients with recurrent pleural effusion. Ann. Thorac. Surg. 2014, 97, 1872–1876, discussion 1876–1877. [Google Scholar] [CrossRef] [PubMed]
- van Meerbeeck, J.P.; Baas, P.; Debruyne, C.; Smit, E.F.; van Klaveren, R.J.; Galdermans, D.; Lentz, M.A.; Manegold, C.; Giaccone, G.; Group, E.L.C. A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur. J. Cancer 2002, 38, 779–783. [Google Scholar] [CrossRef]
- Tsao, A.S.; Miao, J.; Wistuba, I.I.; Vogelzang, N.J.; Heymach, J.V.; Fossella, F.V.; Lu, C.; Velasco, M.R.; Box-Noriega, B.; Hueftle, J.G.; et al. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naive Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J. Clin. Oncol. 2019, 37, 2537–2547. [Google Scholar] [CrossRef] [Green Version]
- Parikh, K.; Mandrekar, S.J.; Allen-Ziegler, K.; Esplin, B.; Tan, A.D.; Marchello, B.; Adjei, A.A.; Molina, J.R. A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). Oncologist 2020, 25, 523–531. [Google Scholar] [CrossRef] [Green Version]
- Cortinovis, D.; Grosso, F.; Carlucci, L.; Zucali, P.A.; Pasello, G.; Tiseo, M.; Sperandi, F.; Hollander, L.; Galli, F.; Torri, V.; et al. Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study. Clin. Lung Cancer 2021, 22, 361–370.e3. [Google Scholar] [CrossRef]
- Castagneto, B.; Botta, M.; Aitini, E.; Spigno, F.; Degiovanni, D.; Alabiso, O.; Serra, M.; Muzio, A.; Carbone, R.; Buosi, R.; et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann. Oncol. 2008, 19, 370–373. [Google Scholar] [CrossRef]
- Katirtzoglou, N.; Gkiozos, I.; Makrilia, N.; Tsaroucha, E.; Rapti, A.; Stratakos, G.; Fountzilas, G.; Syrigos, K.N. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: A phase II study. Clin. Lung Cancer 2010, 11, 30–35. [Google Scholar] [CrossRef]
- Srour, S.A.; Stoner, J.A. Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis. J. Clin. Oncol. 2016, 34, 8554. [Google Scholar] [CrossRef]
- Dudek, A.Z.; Wang, X.F.F.; Gu, L.; Stinchcombe, T.; Kratzke, R.A.; Vokes, E.E.; Kindler, H.L. Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression after first-line chemotherapy: Cancer and Leukemia Group B (CALGB) 30901 (Alliance). J. Clin. Oncol. 2019, 37, 8517. [Google Scholar] [CrossRef]
- Burgers, S.A.; de Gooijer, C.; Cornelissen, R.; Aerts, J.G.; Biesma, B.; Heemst, R.V.; Youssef-El Soud, M.; Groen, H.J.M.; Staal-van den Brekel, A.J.; Bootsma, G.; et al. Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19). Ann. Oncol. 2019, 30, v931–v932. [Google Scholar] [CrossRef]
- Fennell, D.A.; Baas, P.; Taylor, P.; Nowak, A.K.; Gilligan, D.; Nakano, T.; Pachter, J.A.; Weaver, D.T.; Scherpereel, A.; Pavlakis, N.; et al. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. J. Clin. Oncol. 2019, 37, 790–798. [Google Scholar] [CrossRef]
- Ceresoli, G.L.; Aerts, J.G.; Dziadziuszko, R.; Ramlau, R.; Cedres, S.; van Meerbeeck, J.P.; Mencoboni, M.; Planchard, D.; Chella, A.; Crino, L.; et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): A multicentre, single-arm phase 2 trial. Lancet Oncol. 2019, 20, 1702–1709. [Google Scholar] [CrossRef]
- Scagliotti, G.V.; Gaafar, R.; Nowak, A.K.; Nakano, T.; van Meerbeeck, J.; Popat, S.; Vogelzang, N.J.; Grosso, F.; Aboelhassan, R.; Jakopovic, M.; et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): A double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir. Med. 2019, 7, 569–580. [Google Scholar] [CrossRef]
- Scherpereel, A.; Mazieres, J.; Greillier, L.; Lantuejoul, S.; Do, P.; Bylicki, O.; Monnet, I.; Corre, R.; Audigier-Valette, C.; Locatelli-Sanchez, M.; et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019, 20, 239–253. [Google Scholar] [CrossRef]
- Peters, S.; Scherpereel, A.; Cornelissen, R.; Oulkhouir, Y.; Greillier, L.; Kaplan, M.A.; Talbot, T.; Monnet, I.; Hiret, S.; Baas, P.; et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann. Oncol. 2022; in press. [Google Scholar] [CrossRef]
- Nowak, A.K.; Lesterhuis, W.J.; Hughes, B.G.M.; Brown, C.; Kok, P.S.; O’Byrne, K.J.; John, T.; Pavlakis, N.; Kao, S.C.H.; Yip, S.; et al. DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma-First results. J. Clin. Oncol. 2018, 36, 8503. [Google Scholar] [CrossRef]
- Forde, P.M.; Sun, Z.; Anagnostou, V.; Kindler, H.L.; Purcell, W.T.; Goulart, B.H.L.; Dudek, A.Z.; Borghaei, H.; Brahmer, J.R.; Ramalingam, S.S. PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study. ASCO Virtual Sci. Program 2020, 38, 9003. [Google Scholar] [CrossRef]
- Manegold, C.; Symanowski, J.; Gatzemeier, U.; Reck, M.; von Pawel, J.; Kortsik, C.; Nackaerts, K.; Lianes, P.; Vogelzang, N.J. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann. Oncol. 2005, 16, 923–927. [Google Scholar] [CrossRef]
- Muers, M.F.; Stephens, R.J.; Fisher, P.; Darlison, L.; Higgs, C.M.; Lowry, E.; Nicholson, A.G.; O’Brien, M.; Peake, M.; Rudd, R.; et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): A multicentre randomised trial. Lancet 2008, 371, 1685–1694. [Google Scholar] [CrossRef] [Green Version]
- Petrelli, F.; Ardito, R.; Conti, B.; Coinu, A.; Cabiddu, M.; Ghilardi, M.; Borgonovo, K.; Barni, S.; Ghidini, A. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. Respir. Med. 2018, 141, 72–80. [Google Scholar] [CrossRef] [PubMed]
- Taylor, P.; Castagneto, B.; Dark, G.; Marangolo, M.; Scagliotti, G.V.; van Klaveren, R.J.; Labianca, R.; Serke, M.; Schuette, W.; van Meerbeeck, J.P.; et al. Single-agent pemetrexed for chemonaive and pretreated patients with malignant pleural mesothelioma: Results of an International Expanded Access Program. J. Thorac. Oncol. 2008, 3, 764–771. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ceresoli, G.L.; Zucali, P.A.; Gianoncelli, L.; Lorenzi, E.; Santoro, A. Second-line treatment for malignant pleural mesothelioma. Cancer Treat. Rev. 2010, 36, 24–32. [Google Scholar] [CrossRef]
- Zauderer, M.G.; Kass, S.L.; Woo, K.; Sima, C.S.; Ginsberg, M.S.; Krug, L.M. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer 2014, 84, 271–274. [Google Scholar] [CrossRef] [Green Version]
- Pinto, C.; Zucali, P.A.; Pagano, M.; Grosso, F.; Pasello, G.; Garassino, M.C.; Tiseo, M.; Soto Parra, H.; Grossi, F.; Cappuzzo, F.; et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021, 22, 1438–1447. [Google Scholar] [CrossRef]
- Fennell, D.A.; Casbard, A.C.; Porter, C.; Rudd, R.; Lester, J.F.; Nicolson, M.; Morgan, B.; Steele, J.P.; Darlison, L.; Gardner, G.M.; et al. A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma. J. Clin. Oncol. 2021, 39, 8507. [Google Scholar] [CrossRef]
- Popat, S.; Curioni-Fontecedro, A.; Dafni, U.; Shah, R.; O’Brien, M.; Pope, A.; Fisher, P.; Spicer, J.; Roy, A.; Gilligan, D.; et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: The European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann. Oncol. 2020, 31, 1734–1745. [Google Scholar] [CrossRef]
- Okada, M.; Kijima, T.; Aoe, K.; Kato, T.; Fujimoto, N.; Nakagawa, K.; Takeda, Y.; Hida, T.; Kanai, K.; Imamura, F.; et al. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Clin. Cancer Res. 2019, 25, 5485–5492. [Google Scholar] [CrossRef] [Green Version]
- Fujimoto, N.; Okada, M.; Kijima, T.; Aoe, K.; Kato, T.; Nakagawa, K.; Takeda, Y.; Hida, T.; Kanai, K.; Hirano, J.; et al. Clinical Efficacy and Safety of Nivolumab in Japanese Patients With Malignant Pleural Mesothelioma: 3-Year Results of the MERIT Study. JTO Clin. Res. Rep. 2021, 2, 100135. [Google Scholar] [CrossRef]
- Fennell, D.A.; Ewings, S.; Ottensmeier, C.; Califano, R.; Hanna, G.G.; Hill, K.; Danson, S.; Steele, N.; Nye, M.; Johnson, L.; et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): A multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021, 22, 1530–1540. [Google Scholar] [CrossRef]
- Calabro, L.; Morra, A.; Fonsatti, E.; Cutaia, O.; Amato, G.; Giannarelli, D.; Di Giacomo, A.M.; Danielli, R.; Altomonte, M.; Mutti, L.; et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. Lancet Oncol. 2013, 14, 1104–1111. [Google Scholar] [CrossRef]
- Calabro, L.; Morra, A.; Fonsatti, E.; Cutaia, O.; Fazio, C.; Annesi, D.; Lenoci, M.; Amato, G.; Danielli, R.; Altomonte, M.; et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study. Lancet Respir. Med. 2015, 3, 301–309. [Google Scholar] [CrossRef]
- Calabro, L.; Morra, A.; Giannarelli, D.; Amato, G.; D’Incecco, A.; Covre, A.; Lewis, A.; Rebelatto, M.C.; Danielli, R.; Altomonte, M.; et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): An open-label, non-randomised, phase 2 study. Lancet Respir. Med. 2018, 6, 451–460. [Google Scholar] [CrossRef]
- Calabro, L.; Rossi, G.; Morra, A.; Rosati, C.; Cutaia, O.; Daffina, M.G.; Altomonte, M.; Di Giacomo, A.M.; Casula, M.; Fazio, C.; et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: A follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir. Med. 2021, 9, 969–976. [Google Scholar] [CrossRef]
- Raskin, J.; Surmont, V.; Cornelissen, R.; Baas, P.; van Schil, P.E.Y.; van Meerbeeck, J.P. A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205). Transl. Lung Cancer Res. 2018, 7, 593–598. [Google Scholar] [CrossRef]
- Van Schil, P.E.; Baas, P.; Gaafar, R.; Maat, A.P.; Van de Pol, M.; Hasan, B.; Klomp, H.M.; Abdelrahman, A.M.; Welch, J.; van Meerbeeck, J.P.; et al. Trimodality therapy for malignant pleural mesothelioma: Results from an EORTC phase II multicentre trial. Eur. Respir. J. 2010, 36, 1362–1369. [Google Scholar] [CrossRef] [Green Version]
- Flores, R.M.; Krug, L.M.; Rosenzweig, K.E.; Venkatraman, E.; Vincent, A.; Heelan, R.; Akhurst, T.; Rusch, V.W. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: A phase II trial. J. Thorac. Oncol. 2006, 1, 289–295. [Google Scholar] [CrossRef]
- Krug, L.M.; Pass, H.I.; Rusch, V.W.; Kindler, H.L.; Sugarbaker, D.J.; Rosenzweig, K.E.; Flores, R.; Friedberg, J.S.; Pisters, K.; Monberg, M.; et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol. 2009, 27, 3007–3013. [Google Scholar] [CrossRef] [Green Version]
- Trovo, M.; Relevant, A.; Polesel, J.; Muraro, E.; Barresi, L.; Drigo, A.; Baresic, T.; Bearz, A.; Fanetti, G.; Del Conte, A.; et al. Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. Int. J. Radiat. Oncol. Biol. Phys. 2021, 109, 1368–1376. [Google Scholar] [CrossRef]
- Rimner, A.; Hu, C.; Rusch, V.W.; Gill, R.R.; Simone, C.B.; Zauderer, M.; Yorke, E.D.; Li, Z.; Peikert, T.D.; Voong, R.; et al. A Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) (NRG LU-006). Int. J. Radiat. Oncol. Biol. Phys. 2021, 111, E463–E464. [Google Scholar] [CrossRef]
- Patel, R.; Ludmir, E.B.; Miccio, J.A.; Menon, H.; Barsky, A.R.; Mesko, S.M.; Kodali, M.; Lautenschlaeger, T.; Adeberg, S.; Simone, C.B., 2nd; et al. Disease-Related Outcomes and Toxicities of Intensity Modulated Radiation Therapy After Lung-Sparing Pleurectomy for Malignant Pleural Mesothelioma: A Systematic Review. Pract. Radiat. Oncol. 2020, 10, 423–433. [Google Scholar] [CrossRef]
- Shah, R.; Klotz, L.V.; Chung, I.; Feisst, M.; Schneider, M.A.; Riedel, J.; Bischoff, H.; Eichhorn, M.E.; Thomas, M. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. Clin. Lung Cancer 2021, 22, 142–146. [Google Scholar] [CrossRef]
- Dumoulin, D.W.; Cornelissen, R.; Bezemer, K.; Baart, S.J.; Aerts, J. Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. Vaccines 2021, 9, 525. [Google Scholar] [CrossRef]
- Hiltbrunner, S.; Britschgi, C.; Schuberth, P.; Bankel, L.; Nguyen-Kim, T.D.L.; Gulati, P.; Weder, W.; Opitz, I.; Lauk, O.; Caviezel, C.; et al. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: First report of FAPME, a phase I clinical trial. Ann. Oncol. 2021, 32, 120–121. [Google Scholar] [CrossRef]
- Castelletti, L.; Yeo, D.; van Zandwijk, N.; Rasko, J.E.J. Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. Biomark. Res. 2021, 9, 11. [Google Scholar] [CrossRef]
- Thapa, B.; Salcedo, A.; Lin, X.; Walkiewicz, M.; Murone, C.; Ameratunga, M.; Asadi, K.; Deb, S.; Barnett, S.A.; Knight, S.; et al. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. J. Thorac. Oncol. 2017, 12, 850–859. [Google Scholar] [CrossRef] [Green Version]
- Yap, T.A.; Aerts, J.G.; Popat, S.; Fennell, D.A. Novel insights into mesothelioma biology and implications for therapy. Nat. Rev. Cancer 2017, 17, 475–488. [Google Scholar] [CrossRef]
- Pastorino, S.; Yoshikawa, Y.; Pass, H.I.; Emi, M.; Nasu, M.; Pagano, I.; Takinishi, Y.; Yamamoto, R.; Minaai, M.; Hashimoto-Tamaoki, T.; et al. A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. J. Clin. Oncol. 2018, 36, 3485–3494. [Google Scholar] [CrossRef]
- Sage, A.P.; Martinez, V.D.; Minatel, B.C.; Pewarchuk, M.E.; Marshall, E.A.; MacAulay, G.M.; Hubaux, R.; Pearson, D.D.; Goodarzi, A.A.; Dellaire, G.; et al. Genomics and Epigenetics of Malignant Mesothelioma. High-Throughput 2018, 7, 20. [Google Scholar] [CrossRef] [Green Version]
- Hiltbrunner, S.; Fleischmann, Z.; Sokol, E.; Curioni-Fontecedro, A. 1734P Genomic landscape of pleural and peritoneal mesothelioma tumors. Ann. Oncol. 2021, 32, S1200. [Google Scholar] [CrossRef]
- Oehl, K.; Vrugt, B.; Wagner, U.; Kirschner, M.B.; Meerang, M.; Weder, W.; Felley-Bosco, E.; Wollscheid, B.; Bankov, K.; Demes, M.C.; et al. Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. Clin. Cancer Res. 2021, 27, 2277–2291. [Google Scholar] [CrossRef]
- Fennell, D.A.; King, A.; Mohammed, S.; Branson, A.; Brookes, C.; Darlison, L.; Dawson, A.G.; Gaba, A.; Hutka, M.; Morgan, B.; et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): An open-label, single-arm, phase 2a clinical trial. Lancet Respir. Med. 2021, 9, 593–600. [Google Scholar] [CrossRef]
- Fennell, D.A.; King, A.; Mohammed, S.; Greystoke, A.; Anthony, S.; Poile, C.; Nusrat, N.; Scotland, M.; Bhundia, V.; Branson, A.; et al. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): A single-arm, open-label, phase 2 trial. Lancet Oncol. 2022; in press. [Google Scholar] [CrossRef]
- Beddowes, E.; Spicer, J.; Chan, P.Y.; Khadeir, R.; Corbacho, J.G.; Repana, D.; Steele, J.P.; Schmid, P.; Szyszko, T.; Cook, G.; et al. Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. J. Clin. Oncol. 2017, 35, 1778–1785. [Google Scholar] [CrossRef] [Green Version]
- Szlosarek, P.W.; Steele, J.P.; Nolan, L.; Gilligan, D.; Taylor, P.; Spicer, J.; Lind, M.; Mitra, S.; Shamash, J.; Phillips, M.M.; et al. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. JAMA Oncol. 2017, 3, 58–66. [Google Scholar] [CrossRef]
- Chang, K.; Pastan, I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 1996, 93, 136–140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hassan, R.; Alewine, C.; Mian, I.; Spreafico, A.; Siu, L.L.; Gomez-Roca, C.; Delord, J.P.; Italiano, A.; Lassen, U.; Soria, J.C.; et al. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin. Cancer 2020, 126, 4936–4947. [Google Scholar] [CrossRef] [PubMed]
- Hassan, R.; Alley, E.; Kindler, H.; Antonia, S.; Jahan, T.; Honarmand, S.; Nair, N.; Whiting, C.C.; Enstrom, A.; Lemmens, E.; et al. Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma. Clin. Cancer Res. 2019, 25, 5787–5798. [Google Scholar] [CrossRef]
- Adusumilli, P.S.; Zauderer, M.G.; Riviere, I.; Solomon, S.B.; Rusch, V.W.; O’Cearbhaill, R.E.; Zhu, A.; Cheema, W.; Chintala, N.K.; Halton, E.; et al. A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. Cancer Discov. 2021, 11, 2748–2763. [Google Scholar] [CrossRef]
- Hassan, R.; Blumenschein, G.R., Jr.; Moore, K.N.; Santin, A.D.; Kindler, H.L.; Nemunaitis, J.J.; Seward, S.M.; Thomas, A.; Kim, S.K.; Rajagopalan, P.; et al. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. J. Clin. Oncol. 2020, 38, 1824–1835. [Google Scholar] [CrossRef] [PubMed]
Trial | Drug | n | Maintenance | Histo | PE | PRO/QoL |
---|---|---|---|---|---|---|
NCT02899299 (Checkmate-743) | Nivolumab + Ipilimumab vs. Cisplatin or Carboplatin + Pemetrexed | 605 | Nivolumab + Ipilimumab for up to of 2 years * | All | OS | EQ-5D-3L, LCSS-Meso |
NCT02784171 (Canadian Cancer Trials Group) | Pembrolizumab + Cisplatin + Pemetrexed vs. Cisplatin + Pemetrexed | 520 | Pembrolizumab for up to 2 years * | All | OS | QLQ-C30 |
NCT04334759 (DREAM3R) | Durvalumab + Cisplatin or Carboplatin + Pemetrexed vs. Cisplatin or Carboplatin + Pemetrexed | 480 | Durvalumab for up to 12 months * | All | OS | EQ-5D-5L, QLQ-LC29 |
NCT03762018 (BEAT-Meso) | Bevacizumab + Atezolizumab + Carboplatin + Pemetrexed vs. Carboplatin + Pemetrexed + Bevacizumab | 320 | Bevacizumab + Atezolizumab * | All | OS | PRO/QoL |
Trial | MAPS-2 | INITIATE | NIBIT-Meso-1 |
---|---|---|---|
Drug | Nivolumab + Ipilimumab | Nivolumab + Ipilimumab | Durvalumab + Tremelimumab |
n | 62 | 34 | 40 |
PR (%) | 28 | 29 | 28 |
DCR (%) | 52 | 68 | 65 |
PD (%) | 42 | 32 | 35 |
mPFS (mo.) | 5.6 | 6.2 | 8 |
mOS (mo.) | 15.9 | NR (12.7-NR) | 16.6 |
Trial | n (-N) | Neoadjuvant | Adjuvant |
---|---|---|---|
NCT04177953 (NICITA) | 92 1:1 | none | Platin/Pemetrexed ± Nivolumab |
NCT04996017 | 162 2:1 | Chemotherapy allowed | Chemotherapy allowed + Atezolizumab |
NCT02707666 | 15 | Pembrolizumab | Platin/Pemetrexed |
NCT03228537 | 28 | Atezolizumab + Platin/Pemetrexed | Radiotherapy |
NCT02592551 | 20 | none | |
−8 | Durvalumab, | ||
−8 | Durvalumab + Tremelimumab, | ||
−4 | Placebo | ||
NCT03918252 | 30 | none | |
−15 | Nivolumab | ||
−15 | Nivolumab + Ipilimumab |
NCT Number | Trial | Abbreviation | n |
---|---|---|---|
NCT04287829 | Pembrolizumab plus lenvatinib in second line and third line malignant pleural mesothelioma patients | PEMMELA | 36 |
NCT05005429 | Study of the efficacy and safety of the bintrafusp alfa in previously treated advanced malignant pleural mesothelioma | BIMES | 47 |
NCT03126630 | Pembrolizumab with or without anetumab ravtansine in treating patients with mesothelin-positive pleural mesothelioma | 110 | |
NCT02709512 | Phase 2/3 study in subjects with MPM to assess ADI-PEG 20 with pemetrexed and cisplatin | ATOMIC | 386 |
NCT04300244 | Nivolumab and ipilimumab +/− UV1 vaccination as second line treatment in patients with malignant mesothelioma | NIPU | 118 |
NCT03710876 | Efficacy & safety of rAd-IFN administered with celecoxib & gemcitabine in patients with malignant pleural mesothelioma | INFINITE | 53 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Shah, R.; Klotz, L.V.; Glade, J. Current Management and Future Perspective in Pleural Mesothelioma. Cancers 2022, 14, 1044. https://doi.org/10.3390/cancers14041044
Shah R, Klotz LV, Glade J. Current Management and Future Perspective in Pleural Mesothelioma. Cancers. 2022; 14(4):1044. https://doi.org/10.3390/cancers14041044
Chicago/Turabian StyleShah, Rajiv, Laura V. Klotz, and Julia Glade. 2022. "Current Management and Future Perspective in Pleural Mesothelioma" Cancers 14, no. 4: 1044. https://doi.org/10.3390/cancers14041044